AbbVie EVP receives new stock and option awards

AbbVie executive Nicholas Donoghoe reported multiple equity awards tied to performance goals.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

AbbVie executive Nicholas Donoghoe reported multiple equity awards tied to performance goals. On February 18, 2026, he acquired an option to buy 20,312 AbbVie shares, vesting in three equal annual installments starting on February 18, 2027.

He also received performance-based stock awards of 13,031, 4,632, 5,172 and 6,222 AbbVie shares. These stock units vested after AbbVie’s Compensation Committee certified achievements in earnings per share, relative total shareholder return and relative return on equity, with shares scheduled to be issued on February 28, 2026.

Insider Trade Summary

Grant/Award: 49,369 shares

Grant/Award 5 txns

Insider Donoghoe Nicholas

Role EVP, CHIEF BUS/STRAT OFFICER

Type	Security	Shares	Price	Value
Grant/Award	Option (Right to buy)	20,312	$0.00	$0.00
Grant/Award	Common Stock, $0.01 par value	13,031	$0.00	$0.00
Grant/Award	Common Stock, $0.01 par value	4,632	$0.00	$0.00
Grant/Award	Common Stock, $0.01 par value	5,172	$0.00	$0.00
Grant/Award	Common Stock, $0.01 par value	6,222	$0.00	$0.00

Holdings After Transaction: Option (Right to buy) — 20,312 contracts (Direct); Common Stock, $0.01 par value — 87,304 shares (Direct)

Footnotes (5)

F1. Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
F2. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
F3. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
F4. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.
F5. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,771 on February 18, 2027, 6,771 on February 18, 2028, and 6,770 on February 18, 2029.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AbbVie (ABBV) EVP Nicholas Donoghoe report in this Form 4?

Nicholas Donoghoe reported multiple equity awards from AbbVie, including a stock option for 20,312 shares and several performance-based stock awards. These were granted or vested after AbbVie’s Compensation Committee certified achievement of specific earnings and return metrics.

How many AbbVie shares are covered by Nicholas Donoghoe’s new stock option?

The filing shows an employee stock option covering 20,312 AbbVie shares. It was granted under AbbVie’s Amended and Restated 2013 Incentive Stock Program and becomes exercisable in three annual installments beginning February 18, 2027, subject to the vesting schedule disclosed.

What performance measures affect the AbbVie stock awards to Nicholas Donoghoe?

The stock awards are tied to multiple performance measures, including earnings per share, relative total shareholder return and a relative return on equity metric. Vesting occurred after AbbVie’s Compensation Committee certified achievement of these goals, with share delivery scheduled for February 28, 2026.

When will the vested AbbVie performance stock awards be issued to Nicholas Donoghoe?

The filing states that vested performance-based stock and restricted stock unit awards will be issued on February 28, 2026. Although performance conditions were certified earlier, the actual delivery of AbbVie common shares occurs on that specified future issuance date.

What is the vesting schedule for Nicholas Donoghoe’s AbbVie stock option grant?

The option vests in three annual tranches: 6,771 shares on February 18, 2027, another 6,771 shares on February 18, 2028, and 6,770 shares on February 18, 2029. This staggered schedule gradually makes the entire 20,312-share option exercisable over time.

Are Nicholas Donoghoe’s AbbVie equity awards direct holdings?

Yes. The transactions are reported as directly owned, indicated by the ownership code "D" and direct_or_indirect classification "D". This means the AbbVie common stock and option awards listed are held directly by Nicholas Donoghoe, rather than through an intermediary entity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/20/2026 - 06:35 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Donoghoe Nicholas

(Last)

(First)

(Middle)

1 NORTH WAUKEGAN ROAD

(Street)

NORTH CHICAGO

60064

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, CHIEF BUS/STRAT OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, $0.01 par value	02/18/2026		A		13,031⁽¹⁾	A	$0	71,278	D
Common Stock, $0.01 par value	02/18/2026		A		4,632⁽²⁾	A	$0	75,910	D
Common Stock, $0.01 par value	02/18/2026		A		5,172⁽³⁾	A	$0	81,082	D
Common Stock, $0.01 par value	02/18/2026		A		6,222⁽⁴⁾	A	$0	87,304	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Option (Right to buy)	$230.04	02/18/2026		A		20,312		⁽⁵⁾	02/17/2036	Common Stock	20,312	$0	20,312	D

Explanation of Responses:

1. Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.

2. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.

3. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.

4. Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 13, 2025. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2026.

5. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,771 on February 18, 2027, 6,771 on February 18, 2028, and 6,770 on February 18, 2029.

	/s/ T.O. Odutayo, Attorney-in-Fact for Nicholas J. Donoghoe	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR